Letter: The ethics of using inferior regimens in H. pylori randomised trials - Editors' reply

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 7, 2012, Pages 858-

  Pounder, R E ^a   Talley, N J ^a  

^a Alimentary Pharmacology and Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; CLINICAL RESEARCH; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HELICOBACTER INFECTION; HUMAN; INFECTION CONTROL; LETTER; MEDICAL ETHICS; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION;

EID: 84858165566     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05024.x     Document Type: Letter

References (6)

1. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al,. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
2. Kim YS, Kim SJ, Yoon JH, et al,. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-105.
3. Park HG, Jung MK, Jung JT, et al,. Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012; 35: 56-65.
4. Graham DY, Fischbach LA,. Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther 2012; 35: 852-4.
5. Anthony O'Connor JP, O'Morain CA,. Letter: the ethics of using inferior regimens in H. pylori randomised trials-invited comment. Aliment Pharmacol Ther 2012; 35: 854-6.
6. Gisbert JP,. Letter: the ethics of using inferior regimens in H. pylori randomised trials-invited comment. Aliment Pharmacol Ther 2012; 35: 856-7.